The Lundbeck Neuroscience Symposium was held at Sofitel KL Damansara over 2 days, with extensivediscussions on the management of various mental illnesses. The second day of the symposiumaddressed the topic of schizophrenia management, focusing on treatment goals, the rationale forpartial dopamine D(2) receptor agonism and the use of long-acting injectable (LAI) antipsychotics topromote adherence.
In this third issue we take
a look at how empagliflozin made a bold impact on clinical guidelines across
multiple specialties. We will explore how existing treatment recommendations
were altered, and summarise the current guidelines and future perspectives of
At a GSK-sponsored symposium during the 15th Asian & Oceanian Congress of Child Neurology 2019, held in conjunction with the 41st Malaysian Paediatric Association Annual Congress at Shangri-La Hotel Kuala Lumpur, Dato’ Dr Musa Mohd Nordin spoke about the current state of VPDs and expounded the value of combination vaccines in mitigating the risk of infectious disease transmission in the paediatric population.
At the 13th Annual Scientific Meeting of the Malaysian Osteoporosis Society (MOS), Dr Chan Siew Pheng discussed the role of alfacalcidol (One-Alpha®) in the treatment of osteoporosis (OP) and presented several patient profiles where alfacalcidol exhibited efficacy in increasing bone mineral density (BMD).
This second issue revisits the impact EMPA-REG OUTCOME had on clinical
practice and helps readers discover how it gives life back to patients
through its cardiovascular indication. Learn how it was approved and the
mechanisms for its cardiovascular benefits.
Heart failure (HF) is a global public health concern, affecting about 38 million individuals globally.1 Several studies suggest a rising prevalence of HF, which could be attributed to the ageing of the population, along with improved HF survival owing to the tremendous advancement in HF therapy.2–4 In this case study, Dato’ Dr Ahmad Murtazam shares his clinical experience in managing a patient with HF and reduced ejection fraction (HFrEF), following acute myocardial infarction (AMI) and multiple hospitalisations.
Dropping aspirin after 3 months of dual therapy with ticagrelor reduced bleeding in patients with diabetes who have undergone PCI* vs taking both agents for 1 year, the TWILIGHT-DM** study has shown, consistent with benefits seen in TWILIGHT for other high-risk patients.
Among patients undergoing complex percutaneous coronary intervention (PCI) who completed 3 months of dual antiplatelet therapy (DAPT) comprising aspirin and the potent P2Y12-receptor inhibitor ticagrelor, aspirin withdrawal led to fewer bleeding episodes without increasing the risk of ischaemic events compared with continued DAPT, according to data from the TWILIGHT-COMPLEX* subanalysis presented at ACC.20/WCC Virtual.
Taking ticagrelor alone — and dropping aspirin — after 3 months of DAPT* post-PCI** significantly reduced bleeding events without increasing the risk of ischaemic adverse events compared with continuing a DAPT of ticagrelor plus aspirin, the TICO*** trial has shown.
This is the first issue in a series of five
articles celebrating the fifth anniversary of EMPA-REG OUTCOME’s trial data
release. This issue brings insight to the trial’s background, study design and
The novel coronavirus disease (COVID-19) pandemic appears to have a significant impact on oncological care, according to a study, which stresses the need for psycho-oncological support for cancer patients.